Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Next-generation conjugates at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

30 organizations at Discovery on Target 2026 present work in next-generation conjugates: 17 drug developers, 9 academic, government and non-profit bodies and 4 technology and service providers. Between them they bring 66 presentations to the program. Most represented: Pfizer (9 on the program), AstraZeneca (7 on the program), Novartis (5 on the program). As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–9 of 30 organizations

Organization	Discovery on Target 2026 Attendance
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company developing medicines and vaccines in oncology, inflammation and immunology, internal medicine and rare diseases.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Emerging Drug Targets Talk Tue Sep 29 2:20pm–2:50pm Discovery of Potent and Brain-Penetrant Inverse Agonists for GPR61, an Orphan GPCR Emerging Drug Targets Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Modern GPCR-Targeted Drug Discovery Lead Generation Strategies · with Computational Therapeutics Discovery Talk Wed Sep 30 11:50am–12:20pm A GIPR Small-Molecule Antagonist for Obesity Lead Generation Strategies Chair Wed Sep 30 2:00pm–2:05pm Chairperson's Remarks Lead Generation Strategies Talk Wed Sep 30 2:35pm–3:05pm Fragment Screening and Hit Optimization for an Orphan GPCR Using 19F-NMR and SPR Techniques Lead Generation Strategies Panel Thu Oct 1 7:30am–8:15am Building the Next Generation of DEL Datasets for AI Lead Generation Strategies Talk Thu Oct 1 9:35am–10:05am Extracting Actionable SAR from Primary DEL Screens to Drive Early Lead Optimization Lead Generation Strategies Talk Thu Oct 1 3:30pm–4:00pm Antibody-Drug Conjugate Immunogenicity: Current Landscape and Strategies to De-Risk Development Next-Generation Conjugates
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global biopharmaceutical company with medicines in oncology, cardiovascular, respiratory, immunology and rare diseases.	Chair Mon Sep 28 1:30pm–1:35pm Chairperson's Remarks Symposium: Induced Proximity-Based Drug Discovery Panel Tue Sep 29 11:05am–12:05pm Defining Next-Generation Radioligand Therapies: From Molecular Design to Clinical and Commercial Success Radioligand Therapies · with Normunity, Lumina Pharmaceuticals, Ratio Therapeutics +2 more Talk Tue Sep 29 1:50pm–2:20pm From Imaging to Impact: Practical Frameworks for Personalized Dosimetry in Radioligand Therapy Radioligand Therapies Talk Tue Sep 29 2:50pm–3:20pm DegDig: Digging the Fate of Proteins under Degrader Control by Multiplexed Target‑Guided Proteomics in a 384 Well Format Innovative Discovery Technologies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 9:05am–9:35am Advancements in ADCs: Current Trends in Bioconjugation and Site-Specific Conjugation Strategies Next-Generation Conjugates Talk Wed Sep 30 2:05pm–2:35pm Reduced Time-Point Dosimetry in Radioconjugate Therapy: From Preclinical Models to Clinical Translation Radioligand Therapies Panel Wed Sep 30 3:05pm–4:05pm From Target to Therapy: Science, Strategy, and Scalability Radioligand Therapies · with Perceptive, Curium, Mariana Oncology +1 more Panel Thu Oct 1 7:30am–8:15am Connect the DOTs: Career Growth Opportunities Plenary · with Avacta Therapeutics
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company; Novartis Biomedical Research is its drug discovery arm.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with Barcelona Supercomputing Center, InduPro, Foghorn Therapeutics Talk Tue Sep 29 2:20pm–2:50pm From PSMA to What’s Next: Evolving the Radioligand Target Landscape Radioligand Therapies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 2:05pm–2:35pm Exploring the Impact of Ligand and Payload Design on ADC Therapeutic Index Using Quantitative Systems Pharmacology and Physiologically Based Pharmacokinetic Modeling Next-Generation Conjugates Panel Thu Oct 1 7:30am–8:15am Direct-to-Biology (D2B) Lead Generation Strategies
Massachusetts Institute of Technology Cambridge, Massachusetts
	Talk Wed Sep 30 9:35am–10:05am Antibody Discovery against Intrinsically Disordered Proteins Antibodies Against Challenging Targets Talk Wed Sep 30 11:50am–12:20pm Peptide–Small Molecule Conjugate Libraries for Hit Discovery and Catalyst Development Next-Generation Conjugates Panel Thu Oct 1 2:25pm–3:20pm Starting Up: Translating Lab Ideas into Commercial Impact Plenary · with Portal Biotechnologies, Kiral Medicines, AIRNA +3 more Talk Thu Oct 1 4:05pm–4:35pm Label-Free Single-Cell Buoyant Mass Profiling Uncovers Hidden T-Cell Heterogeneity and Predicts Immunotherapy Response Innovative Discovery Technologies
EMD Serono
emdserono.com Large pharma US and Canadian healthcare business of Merck KGaA, Darmstadt, Germany, developing medicines in oncology, neurology and fertility.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Next-Generation Conjugates Panel Wed Sep 30 7:30am–8:15am Collaborative Conversations for Women in Science Plenary · with Johnson & Johnson, Moderna Talk Wed Sep 30 10:35am–11:05am POSTER SPOTLIGHT: Prime Editing to Create Near Pure Cysteine Mutant Cell Pools for Covalent Inhibitor Validation Emerging Drug Targets Talk Thu Oct 1 12:20pm–12:50pm Targeted PROTAC Delivery: Principles of Crafting PROTAC-ADCs and Self-Assembling PROxAb Shuttles Next-Generation Conjugates
WuXi AppTec Shanghai, China	◆Premier Sponsor
wuxiapptec.com CROs & CDMOsPremier Sponsor Chinese contract research, development and manufacturing group covering chemistry, biology, DNA-encoded library screening, testing and production for drug developers.	Booth Exhibiting at Booth 403 Tue, Sep 293:50pm–7:00pmWed, Sep 3011:05am–4:50pmThu, Oct 111:05am–2:15pm Talk Tue Sep 29 3:20pm–3:50pm Exploration of Novel E3 Ligase to Support Targeted Protein Degradation Drug Discovery Novel Drug Modalities Talk Thu Oct 1 1:00pm–1:30pm Accelerating the Discovery of Next-Gen Oligonucleotide Conjugates: From Hit Identification to CMC Readiness Next-Generation Conjugates
A AbTx
Biotech French start-up developing antibody fragment–drug conjugates for solid tumors with an enzymatic, site-specific conjugation platform.	Chair Wed Sep 30 9:00am–9:05am Chairperson's Remarks Next-Generation Conjugates Talk Wed Sep 30 2:35pm–3:05pm Smaller ADC Formats Based on Therano Stick Technology Could Make the Difference for Solid Tumors Next-Generation Conjugates
Avacta Therapeutics London, UK
avacta.com Biotech Develops pre\|CISION cancer drugs kept inactive by a peptide that the tumor enzyme FAP removes.	Panel Thu Oct 1 7:30am–8:15am Connect the DOTs: Career Growth Opportunities Plenary · with AstraZeneca Talk Thu Oct 1 11:50am–12:20pm Avacta's Proprietary pre\|CISION Technology Facilitates Delivery of pre\|CISION Medicines Specifically to the Tumor Microenvironment Next-Generation Conjugates
Binghamton University Binghamton, NY
binghamton.edu Academic & healthcare Public research university in the State University of New York system.	Panel Wed Sep 30 7:30am–8:15am Challenges and Opportunities for Immune-Modulating Antibody Conjugates Next-Generation Conjugates Talk Wed Sep 30 9:35am–10:20am Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability Next-Generation Conjugates